Format

Send to

Choose Destination
Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Author information

1
University of Texas MD Anderson Cancer Center, Houston, TX, USA fravandi@mdanderson.org.
2
Weill Cornell Medical Center, New York, NY, USA.
3
Indiana University Simon Cancer Center, Indianapolis, IN, USA.
4
Moffitt Cancer Center, Tampa, FL, USA.
5
West Virginia University, Morgantown, WV, USA.
6
Institut Paoli-Calmettes and Aix-Marseille University, Marseille, France.
7
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
8
David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
9
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
10
Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, France.
11
University Hospital Schleswig-Holstein, Kiel, Germany.
12
Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III, Centre Hospitalier Universitaire de Toulouse, France.
13
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
14
IRCCS AOU San Martino-IST, Genova, Italy.
15
Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
16
Universitätsklinikum Münster, Germany.
17
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA.
18
Medical University of South Carolina, Charleston, SC, USA.
PMID:
29794146
DOI:
10.3324/haematol.2018.191361
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center